- Home
- KALV vs SAGE Comparison
KALV vs SAGE Comparison
Compare KALV & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- SAGE
- Stock Information
- Founded
- KALV N/A
- SAGE 2010
- Country
- KALV United States
- SAGE United States
- Employees
- KALV N/A
- SAGE N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- KALV Health Care
- SAGE Health Care
- Exchange
- KALV Nasdaq
- SAGE Nasdaq
- Market Cap
- KALV 418.1M
- SAGE 462.2M
- IPO Year
- KALV N/A
- SAGE 2014
- Fundamental
- Price
- KALV $8.36
- SAGE $5.61
- Analyst Decision
- KALV Strong Buy
- SAGE Hold
- Analyst Count
- KALV 6
- SAGE 19
- Target Price
- KALV $26.25
- SAGE $11.53
- AVG Volume (30 Days)
- KALV 421.6K
- SAGE 1.1M
- Earning Date
- KALV 12-31-2024
- SAGE 02-12-2025
- Dividend Yield
- KALV N/A
- SAGE N/A
- EPS Growth
- KALV N/A
- SAGE N/A
- EPS
- KALV N/A
- SAGE N/A
- Revenue
- KALV N/A
- SAGE $106,399,000.00
- Revenue This Year
- KALV N/A
- SAGE N/A
- Revenue Next Year
- KALV N/A
- SAGE $122.78
- P/E Ratio
- KALV N/A
- SAGE N/A
- Revenue Growth
- KALV N/A
- SAGE 837.60
- 52 Week Low
- KALV $7.98
- SAGE $4.62
- 52 Week High
- KALV $16.88
- SAGE $28.26
- Technical
- Relative Strength Index (RSI)
- KALV 36.75
- SAGE 50.27
- Support Level
- KALV $8.48
- SAGE $4.94
- Resistance Level
- KALV $9.30
- SAGE $5.91
- Average True Range (ATR)
- KALV 0.65
- SAGE 0.36
- MACD
- KALV -0.06
- SAGE 0.02
- Stochastic Oscillator
- KALV 17.12
- SAGE 69.07
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.